Skip to main content

Table 5 Clinical trials of bevacizumab + radiochemotherapy as pre-operative treatment of locally advanced rectal cancer

From: A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

Author and regimen No. of patients pCR (yp T0-N0; %) T-downstaging (%) Grade 3 most common toxicities
Willet [11]     
 BVZ + 5FU + RT 32 16a 50 Diarrhea and hypertension
Spigel [9]     
 BVZ + 5FU + RT 35 29 NA Diarrhea
Crane [6]     
 BVZ + CAP + RT 25 32 64 Perianal desquamation
Velenik [10]     
 BVZ + CAP + RT 61 13 45 Dermatitis
Kennecke [7]     
 BVZ + CAP + OX + RT 42 18 NA Diarrhea
Nogue [8]     
 BVZ + XELOX → BVZ + CAP + RT 47 36 NA Rectal tenesmus
Salazar (current study)     
 BVZ + CAP + RT 44 16 26 Astenia/fatigue
 CAP + RT 46 11 18
  1. Abbreviations: pCR pathological complete response, BVZ bevacizumab, 5FU 5-fluorouracil, CAP capecitabine, OX oxaliplatin, XELOX capecitabine + oxaliplatin, RT radiotherapy, NA not available.
  2. aypT0.